MDUFMA Reauthorization Agreement Is In Place – AdvaMed
This article was originally published in The Gray Sheet
Executive Summary
The medical device industry has reached an agreement with FDA on what will be included in updated user fee legislation, according to AdvaMed President Steve Ubl
You may also be interested in...
In Lead-Up To MDUFMA II, Sen. Hatch Presses FDA On User Fee Trigger Issue
Utah Republican Senator Orrin Hatch is pushing FDA to reconsider its apparent position on how device user fees should be activated on an annual basis under reauthorized legislation
In Lead-Up To MDUFMA II, Sen. Hatch Presses FDA On User Fee Trigger Issue
Utah Republican Senator Orrin Hatch is pushing FDA to reconsider its apparent position on how device user fees should be activated on an annual basis under reauthorized legislation
Industry Favors Predictability Over Speed In Next Round Of MDUFMA
Senior device industry staffers are more interested in improving the predictability of FDA's premarket review process than pushing the agency to accelerate its performance, an FDA 1report suggests